Table 1.
Variable | No. of Patients (%) | |
---|---|---|
Age (years); Median (range) | 61 (37–76) | |
Cutaneous primary | 21 (70) | |
Unknown primary | 8 (27) | |
Mucosal | 1 (3) | |
Gender | Female | 12 (40) |
Male | 18 (60) | |
Performance Status |
0 | 16 (53) |
1 | 14 (47) | |
BRAF mutation (+) | 8 (27) | |
BRAF wild type | 13 (43) | |
Unknown | 9 (30) | |
Recurrent disease after prior surgery | 15 (50) | |
Presence of in-transit metastases | 16 (53) | |
Prior adjuvant HDI | 5 (17) | |
Estimated risk Stage |
IIIB | 3 (10) |
IIIC | 25 (83) | |
*IV (Not eligible) | 2 (7) |
HDI: High-dose interferon-a; ECOG: Eastern Cooperative Oncology Group.